$FBRX News

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow

Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study

Forte Biosciences Reports Results From FB102 Double-Blind Placebo-Controlled Phase 1b Study In Vitiligo

Forte Biosciences Files $500M Shelf Registration For Potential Issuance Of Common Stock, Preferred Stock, Debt Securities, Warrants, And Other Securities From Time To Time

Forte Biosciences Q1 EPS $(1.24) Misses $(1.19) Estimate

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.

Reported Earlier, Forte Biosciences Prices $150M Public Offering Of 5.7M Shares At $26.27 Per Share To Fund Clinical Development Of Autoimmune Disease Candidate FB102

Forte Biosciences shares are trading lower after the company announced a proposed public offering.

Forte Biosciences Reveals Proposed Public Offering; No Size Disclosed

Forte Biosciences Q4 EPS $(1.45) Misses $(1.06) Estimate

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know

We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules